logo-loader
viewMatinas BioPharma

Full interview: Matinas BioPharma CMO says upcoming Amarin FDA advisory committee could 'vastly' expand addressable population

Matinas BioPharma Holdings (NYSEAMERICAN:MTNB) Chief Medical Officer Dr Terry Ferguson tells Proactive the New Jersey-based biotech is eagerly awaiting the outcome of Amarin Corporation's (NASDAQ:AMRN) meeting with an FDA advisory committee on Thursday. Dr Ferguson says the AdCom has the ability to potentially "vastly" expand the addressable population by including cardiovascular disease as an indication.

In addition, Dr Ferguson, who joined the New Jersey-based biotech 10 months ago, offered Proactive insight into his professional background, including positions he has held as AstraZeneca PLC (NYSE:AZN) and at Amgen Inc (NASDAQ:AMGN).

Quick facts: Matinas BioPharma

Price: 0.6872 USD

NYSE:MTNB
Market: NYSE
Market Cap: $136.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Matinas BioPharma named herein, including the promotion by the Company of Matinas BioPharma in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Matinas BioPharma to begin dosing HIV patients with...

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) CEO Jerome Jabbour tells Proactive it will begin a Part 2 study of MAT2203 for the treatment of HIV patients with cryptococcal meningitis. Jabbour explains how the New Jersey-based company will begin dosing its first patient in the...

on 02/24/2020

2 min read